Information Provided By:
Fly News Breaks for July 26, 2017
TTPH
Jul 26, 2017 | 08:24 EDT
As noted earlier, Stifel upgraded Tetraphase to Buy from Hold. Analyst Stephen Willey says that the positive top-line results of a trial of the company's bacteria treatment, eravacycline, is an "important" event that lowers the risk regarding the company's ability to sell its products in the U.S. Moreover, he thinks the drug has several attributes that should spur adoption and utilization in the U.S. Target to $15 from $8.
News For TTPH From the Last 2 Days
There are no results for your query TTPH